Skip header and navigation

1 records – page 1 of 1.

Canadian cost- utility analysis of intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura.

https://arctichealth.org/en/permalink/ahliterature124449
Source
J Popul Ther Clin Pharmacol. 2012;19(2):e166-78
Publication Type
Article
Date
2012
Author
Gord Blackhouse
Feng Xie
Mitchell A H Levine
Kaitryn Campbell
Nazila Assasi
Kathryn Gaebel
Daria O'Reilly
Jean- Eric Tarride
Ron Goeree
Author Affiliation
Programs for Assessment of Technology in Health (PATH) Research Institute, McMaster University, Hamilton, Ontario, Canada. blackhou@mcmaster.ca
Source
J Popul Ther Clin Pharmacol. 2012;19(2):e166-78
Date
2012
Language
English
Publication Type
Article
Keywords
Acute Disease
Adrenal Cortex Hormones - economics - therapeutic use
Age Factors
Body Weight
Canada
Child
Cost-Benefit Analysis
Drug Costs
Hospital Costs
Hospitalization - economics
Humans
Immunoglobulins, Intravenous - economics - therapeutic use
Immunologic Factors - economics - therapeutic use
Intracranial Hemorrhages - economics - etiology - prevention & control
Markov Chains
Models, Economic
Platelet Count
Purpura, Thrombocytopenic, Idiopathic - blood - complications - drug therapy - economics
Quality-Adjusted Life Years
Time Factors
Treatment Outcome
Abstract
Idiopathic thrombocytopenic purpura (ITP) is a hematological disorder and can be classified as acute or chronic. The main goal of treatment for acute childhood ITP is the prevention of potentially fatal bleeding complications, the most serious of which is intracranial hemorrhage (ICH). Treatment options for acute childhood ITP include splenectomy, corticosteroids, and blood products such as intravenous immunoglobulin.
The objective was to evaluate, from a Canadian perspective, the cost-effectiveness of intravenous immunoglobulin (IVIG) compared to alternative inpatient treatments for acute childhood idiopathic thrombocytopenic purpura (ITP).
A Markov model with a lifelong time horizon was used to evaluate the costs and quality-adjusted life years (QALYs) for 5 treatments for children hospitalized for ITP: 1) no treatment; 2) IVIG; 3) Anti-D; 4) prednisone; and 5) methylprednisolone. The model predicted the probability of intracranial hemorrhage for each treatment strategy based on the time children spent with platelet counts
PubMed ID
22580389 View in PubMed
Less detail